Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer

Hilmi Kodaz, Lucia Manganaro, Ilhan Hacibekiroglu, Emanuela Anastasi, Valeria Vinci, Esma Turkmen, Matteo Saldari, Bulent Erdogan, Silvia Bernardo, Cagnur Elpen, Sernaz Uzunoglu, Paolo Sollazzo, Irfan Cicin, Laura Ballesio, Eliana Fuggetta, Antonella Giancotti, Maria Grazia Porpora
Tumori · 2015 · vol. 7(1) , pp. 10–18 · doi:10.5301/je.5000209 · PMID:25702671 · W2077944898
Non-randomised trial OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

This retrospective study found that gemcitabine as second- or third-line chemotherapy for platinum–taxane resistant epithelial ovarian cancer provided similar progression-free and overall survival outcomes with manageable toxicity.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

CONCLUSION: In platinum–taxane resistant epithelial ovarian cancer (EOC), we aimed to determine the effectiveness. PATIENTS AND METHODS: Between 2004 and 2013, patients afflicted with platinum–taxane resistant EOC and who were administered a 30-minute i.v. infusion of single-agent gemcitabine at a dose of 1,250 mg/m2 on the 1st, 8th and 15th days, every 28 days, were examined retrospectively. RESULTS: Twenty-six patients with platinum–taxane resistant EOC were included in the study. The overall survival (OS) was 48 months. The median survival after becoming platinum–taxane resistant was 16 months for the study population. Median time to progression (TTP) and median survival after becoming platinum–taxane resistant for patients who received second-line treatment were 3.3 months and 16 months, respectively; for patients who received third-line treatment with gemcitabine, these were 3.7 months and 19 months, respectively. Administration of gemcitabine as second- and third-line chemotherapy in platinum–taxane resistant EOC, provides similar TTP and OS outcomes (p = 0.4, p = 0.9) with a similar response and toxicity rate. CONCLUSIONS: Second- and third-line gemcitabine at a dose of 1,250 mg/m2 on days 1, 8 and 15 every 28 days as a 30-minute i.v. infusion in platinum–taxane resistant EOC is an effective treatment option with a tolerable and manageable toxicity.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antimetabolites, Antineoplastic Deoxycytidine Drug Resistance, Neoplasm Neoplasm Recurrence, Local Neoplasms, Glandular and Epithelial Neoplasms, Glandular and Epithelial Ovarian Neoplasms Ovarian Neoplasms Salvage Therapy Adult Aged Antimetabolites, Antineoplastic Antimetabolites, Antineoplastic Carcinoma, Ovarian Epithelial Deoxycytidine Deoxycytidine Deoxycytidine Drug Administration Schedule Female Gemcitabine

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (64)

Cited by (6)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:15:04.544443+00:00
License: CC0 · commercial use OK